Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Aug 26;3(6):643–649. doi: 10.1016/0958-1669(92)90010-G

Viral proteases as targets for chemotherapeutic intervention

Christopher UT Hellen 1, Eckard Wimmer 1
PMCID: PMC7172713  PMID: 1369416

Abstract

Many viruses encode proteinases that are essential for infectivity, and are consequently attractive chemotherapeutic targets. The biochemistry and structure of the human immunodeficiency virus proteinase have been characterized extensively, and potent peptide-mimetic inhibitors have been developed. Techniques and strategies used to improve the efficiency of these compounds are likely to be applicable to other viral proteinases.

Abbreviations: PR, proteinase

References

References and recommended reading

  • 1.Hellen CUT, Kräusslich H-G, Wimmer E. Proteolytic Processing of Polyproteins in the Replication of RNA Viruses. Biochemistry. 1989;28:9881–9890. doi: 10.1021/bi00452a001. [DOI] [PubMed] [Google Scholar]
  • 2.Welch AR, Woods AS, McNally LM, Cotter RJ, Gibson W. 6th edn. Vol. 88. 1991. A Herpesvirus Maturational Proteinase, Assemblin: Identification of its Gene, Putative Active Site Domain, and Cleavage Site; pp. 10792–10796. (Proc Natl Acad Sci USA). of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; Identification of the proteinase encoded by cytomegalovirus (and by implication other herpesviruses) that cleaves an assembly protein precursor and is therefore essential for virus maturation.
  • 3.Liu F, Roizman B. 6th edn. Vol. 88. 1992. Differentiation of Multiple Domains in the Herpes Simplex Virus 1 Protease Encoded by the UL26 Gene; pp. 2076–2080. (Proc Natl Acad Sci USA). of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; Preliminary characterization of a maturational proteinase encoded by herpes simplex virus 1.
  • 4.Poorman RA, Tomasselli AG, Heinrickson RL, Kézdy F. A Cumulative Specificity Model for Proteases from Human Immunodeficiency Virus Types 1 and 2, Inferred from Statistical Analysis of an Extended Substrate Base. J Biol Chem. 1991;266:14554–14561. of special interest. [PubMed] [Google Scholar]; This model for substrate recognition by HIV PR suggests that a combination of moderate interactions may be sufficient to confer catalytic specificity.
  • 5.Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RAF, Scolnick EM, Sigal IS. 6th edn. Vol. 85. 1988. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity; pp. 4686–4690. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rao JKM, Erickson JW, Wlodawer A. Structural and Evolutionary Relationships Between Retroviral and Eucaryotic Aspartic Proteinases. Biochemistry. 1991;30:4663–4671. doi: 10.1021/bi00233a005. of outstanding interest. [DOI] [PubMed] [Google Scholar]; This paper contains a lucid introduction to the structure of retroviral proteinases and presents a detailed comparison between them and the eukaryotic aspartic proteinases.
  • 7.Tomasselli AG, Howe WJ, Sawyer TK, Wlodawer A, Heinrikson RL. The Complexities of AIDS: an Assessment of the HIV Protease as a Therapeutic Target. Chem Today. 1991;9:6–27. of outstanding interest. [Google Scholar]; An account of the recent progress in substrate-based inhibitor design is complemented by a concise summary of the structure of HIV PR and a clear exposition of its application to structure-based inhibitor design.
  • 8.Norbeck DW, Kempf DJ. HIV Protease Inhibitors. Ann Rep Med Chem. 1991;26:141–150. of special interest. [Google Scholar]; A summary of recent progress in the development of substrate-based HIV PR inhibitors.
  • 9.Ruff JR. HIV Protease: a Novel Chemotherapeutic Target for AIDS. J Med Chem. 1991;34:2305–2314. doi: 10.1021/jm00112a001. of outstanding interest. [DOI] [PubMed] [Google Scholar]; A timely review of the biochemistry of HIV PR and of strategies for the development of substrate-based chemotherapeutic inhibitors.
  • 10.Krausslich H-G, Schneider H, Zybarth G, Carter CA, Wimmer E. Processing of In Vitro-synthesized Gag Precursor Proteins of Human Immunodeficiency Virus (HIV) Type 1 by HIV Proteinase Generated in Escherichia coli. J Virol. 1988;62:4393–4397. doi: 10.1128/jvi.62.11.4393-4397.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dreyer GB, Metcalf BW, Tomaszek TA, Carr TJ, Chandler AC, Hyland L, Fakhoury SA, Magaard VW, Moore ML, Strickler JE. 6th edn. Vol. 86. 1989. Inhibition of Human Immunodeficiency Virus 1 Protease In Vitro: Rational Design of Substrate Analogue Inhibitors; pp. 9752–9756. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Thaisrivongs S, Tomasselli AG, Moon JB, Hui J, McQuade TJ, Turner SR, Strohbach JW, Howe WJ, Tarpley WG, Heinrickson RL. Inhibitors of the Protease from Human Immunodeficiency Virus: Design and Modeling of a Compound Containing a Dihydroxyethylene Isostere Insert with High Binding Affinity and Effective Antiviral Activity. J Med Chem. 1991;34:2344–2356. doi: 10.1021/jm00112a005. of special interest. [DOI] [PubMed] [Google Scholar]; Selective modification of pseudopeptide renin inhibitor at both termini to yield a potent HIV PR inhibitor.
  • 13.Vacca JP, Guare JP, de Solms SJ, Sanders WM, Giuliana EA, Young SD, Darke PL, Zugay J, Sigal IS, Schleif WA. L-687,908, a Potent Hydroxyethylene-containing HIV Protease Inhibitor. J Med Chem. 1991;34:1225–1228. doi: 10.1021/jm00107a050. of special interest. [DOI] [PubMed] [Google Scholar]; The first of series of disclosures [13•–15•,16••] from a group at Merck illustrating strategies to selectively modify termini and side-chain residues to increase potency, reduce size and peptidic character, and to increase solubility (and hence antiviral activity) of hydroxyethylene isostere-based inhibitors. This paper describes the effect of modification of the P1′, P2′ and P3′ residues.
  • 14.Lyle TA, Wiscount CM, Guare JP, Thompson WJ, Anderson PS, Darke PL, Zugay JA, Emini EA, Schleif WA, Quintero JC. Benzocycloalkyl Amines as Novel C-termini for HIV-1 Protease Inhibitors. J Med Chem. 1991;34:1228–1230. doi: 10.1021/jm00107a051. of special interest. [DOI] [PubMed] [Google Scholar]; Incorporation of 1-amino-2-hydroxyindan as a P2′ surrogate allows truncation of hydroxyethylene-containing inhibitors to span only P2-P2′ residues.
  • 15.Young SD, Payne LS, Thompson WJ, Gaffin N, Lyle TA, Britcher SF, Graham SL, Schultz TH, Deana AA, Darke PL. HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: an Investigation into the Role of the P1′ Side Chain on Structure-activity. J Med Chem. 1992;35:1702–1709. doi: 10.1021/jm00088a004. of special interest. [DOI] [PubMed] [Google Scholar]; Systematic modification of the P1′ residue of the lead inhibitors described in [13•,14•] established that side chains unrelated to natural amino acids are tolerated at this position, permitting substitutions that increase solubility and cell penetration.
  • 16.Thompson WJ, Fitzgerald PMD, Holloway MK, Emini EA, Darke PL, McKeever BM, Schleif WA, Quintero JC, Zugay JA, Tucker TJ. Synthesis and Antiviral Activity of a Series of HIV-1 Protease Inhibitors with Functionality Tethered to the P1 or P1′ Substituents: X-ray Crystal Structure Assisted Design. J Med Chem. 1992;35:1685–1701. doi: 10.1021/jm00088a003. of outstanding interest. [DOI] [PubMed] [Google Scholar]; Computer-assisted molecular modelling was used to design derivatives of the lead inhibitor L-685,434 [14•] with increased cell penetration and antiviral potency. An X-ray crystal structure of the inhibited enzyme confirms the modelling predictions.
  • 17.Rich DH, Green J, Toth MV, Marshall GR, Kent SBH. Hydroxyethylamine Analogues of the p17/p24 Substrate Cleavage Site are Tight-binding Inhibitors of the HIV Protease. J Med Chem. 1990;33:1285–1288. doi: 10.1021/jm00167a003. [DOI] [PubMed] [Google Scholar]
  • 18.Rich DH, Sun C-Q, Prasad JVNV, Pathiasseril A, Toth MV, Marshall GR, Clare M, Mueller RA, Houseman K. Evidence for Multiple Binding Modes. 6th edn. Vol. 34. 1991. Effect of Hydroxyl Group Configuration in Hydroxyethylamine Dipeptide Isosteres on HIV Protease Inhibition; pp. 1222–1225. (J Med Chem). of special interest. [DOI] [PubMed] [Google Scholar]; In a series of hydroxyethylamine isostere inhibitors, the preferred diastereomeric configuration of an essential hydroxyl group depended on both the length and nature of the peptide framework. This hydroxyl group is hydrogen bonded to the two catalytic Asp residues, mimicking a reaction pathway intermediate.
  • 19.Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A. Rational Design of Peptide-based HIV Proteinase Inhibitors. Science. 1990;248:358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  • 20.Krohn A, Redshaw S, Ritchie JC, Graves BJ, Hatada MH. Novel Binding Mode of Highly Potent HIV-proteinase Inhibitors Incorporating the (R)-Hydroxyethylamine Isostere. J Med Chem. 1991;34:3340–3342. doi: 10.1021/jm00115a028. of special interest. [DOI] [PubMed] [Google Scholar]; Binding of the hydroxyethylamine inhibitor Ro 31-8959 described in [19] to HIV PR at the S1′ and S2′ subsites follows an unusual pattern, precluding extension beyond the S2′ subsite.
  • 21.Craig JC, Grief C, Mills J, Hockley D, Duncan IB, Roberts NA. Effects of a Specific Inhibitor of HIV Proteinase (RO 31-8959) on Virus Maturation in a Chronically Infected Promonocytic Cell Line (U1) Antivir Chem Chemother. 1991;2:181–186. of outstanding interest. [Google Scholar]; Antiviral activity of the potent HIV inhibitor Ro 31-8959 is sufficient to inhibit acute and chronic infections. The low toxicity of this compound renders it a highly promising antiviral agent in AIDS chemotherapy.
  • 22.Tucker TJ, Lumma JRWC, Payne LS, Wai JM, de Solms SJ, Giuliani EA, Darke PL, Heimbach JC, Zugay JA, Schleif WA. A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity. J Med Chem. 1992;35:2525–2533. doi: 10.1021/jm00092a002. of special interest. [DOI] [PubMed] [Google Scholar]; A novel subclass of potent hydroxyethylamine inhibitors containing a secondary amine isostere in place of the cyclic amine of Ro 31-8959 show differences in structure-activity relationships and in binding mode.
  • 23.Kempf DJ, Norbeck DW, Codavoci L, Wang XC, Paul DA, Knigge MF, Vasavanonda S, Craig-Kennard A, Sadivar A, Rosenbrook W. Structure-based C2 Symmetric Inhibitors of HIV Protease. J Med Chem. 1990;33:2687–2689. doi: 10.1021/jm00172a002. [DOI] [PubMed] [Google Scholar]
  • 24.Erickson J, Neidhart DJ, Vandrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N. Design, Activity and 2.8Å Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease. Science. 1991;249:527–533. doi: 10.1126/science.2200122. of special interest. [DOI] [PubMed] [Google Scholar]; Design of C2 symmetric inhibitors exploiting the perfect symmetry of HIV PR revealed by X-ray crystallography.
  • 25.Bone R, Vacca JP, Anderson PS, Holloway MK. X-ray Crystal Structure of the HIV Protease Complex with L700,417, an Inhibitor with Pseudo-C2 Symmetry. J Am Chem Soc. 1991;113:9382–9384. of special interest. [Google Scholar]; An illustration of the application of X-ray crystallography to rational drug design, which in this instance revealed unoptimized hydrogen bonding and several water-mediated PR-inhibitor interactions.
  • 26.Kempf DJ, Marsh KC, Paul DA, Knigge MF, Norbeck DW, Kohlbrenner WE, Codavoci L, Vasavanonda S, Bryant P, Wang XC. Antiviral and Pharmokinetic Properties of C2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease. Antimicrob Agents Chemother. 1991;35:2209–2214. doi: 10.1128/aac.35.11.2209. of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; This paper illustrates the difficulties in reconciling the competing demands on PR inhibitors for tight hydrophobic interactions with PR subsites, and aqueous solubility required for bioavailability and in vivo efficacy.
  • 27.Swain AL, Miller MM, Green J, Rich DH, Schneider J, Kent SBH, Wlodawer A. 6th edn. Vol. 87. 1990. X-ray Crystallographic Structure of a Complex Between a Synthetic Protease of Human Immunodeficiency Virus 1 and a Substrate-based Hydroxyethyalmine Inhibitor; pp. 8805–8809. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrickson RL, Schneider J, Kent SBH, Wlodawer A. Structure at 2.5Å Resolution of Chemically Synthesized Human Immunodeficiency Virus Type 1 Protease Complexed with a Hydroxyethylene-based Inhibitor. Biochemistry. 1991;30:1600–1609. doi: 10.1021/bi00220a023. of outstanding interest. [DOI] [PubMed] [Google Scholar]; The hydroxyl group of a potent substrate-based inhibitor occupies the position of a water molecule in native PR which, in a new model of the enzymatic mechanism, is proposed to act as the nucleophile in a concerted attack with an acidic proton on the scissile bond.
  • 29.Desjarlais RL, Seiberl GL, Kuntz ID, Furth PS, Alvarez JC, Ortiz de Montellano PR, Decamp DL, Babe LM, Craik CS. 6th edn. Vol. 87. 1990. Structure-based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficiency Virus 1 Protease; pp. 6644–6648. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hellen CUT, Wimmer E. Maturation of Poliovirus Capsid Proteins. Virology. 1992;187:391–397. doi: 10.1016/0042-6822(92)90440-z. of special interest. [DOI] [PubMed] [Google Scholar]; A concise review of the role of three distinct proteolytic activities in the release of capsid proteins from the poliovirus polyprotein and their subsequent assembly into virions.
  • 31.Krausslich H-G, Nicklin MJH, Toyoda H, Etchison D, Wimmer E. Poliovirus Protease 2A Induces Cleavage of Eukaryotic Initiation Factor 4F Polypeptide p220. J Virol. 1989;61:2711–2718. doi: 10.1128/jvi.61.9.2711-2718.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Clark ME, Hämmerle T, Wimmer E, Dasgupta A. Poliovirus Proteinase 3C Converts an Active Form of Transcription Factor IIIC to an Inactive form: a Mechanism for Inhibition of Host Cell Polymerase III Transcription by Poliovirus. EMBO J. 1991;10:2941–2947. doi: 10.1002/j.1460-2075.1991.tb07844.x. of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; The severe inhibition of RNA polymerase III-mediated transcription in polio-infected cells is a result of inactivation of transcription factor IIIC by the proteolytic activity of 3Cpro.
  • 33.Hammerle T, Hellen CUT, Wimmer E. Site-directed Mutagenesis of the Putative Catalytic Triad of Poliovirus 3C Proteinase. J Biol Chem. 1991;266:5412–5416. of special interest. [PubMed] [Google Scholar]; Site-directed mutagenesis experiments suggest that the catalytic triad of polio 3Cpro-(His40, Glu71, Cys149) structurally resembles trypsinlike serine proteinases but differs significantly in its constituent residues.
  • 34.Klan KM, Teterina NL, Marc D, Girard M. Analysis of Putative Active Site Residues of the Poliovirus 3C Protease. Virology. 1991;191:609–619. doi: 10.1016/0042-6822(91)90894-h. of special interest. [DOI] [PubMed] [Google Scholar]; Experiments designed to evaluate two conflicting structural models of polio 3Cpro suggest that Glu71 is a constituent residue of the catalytic triad whereas Asp85 is involved in polyprotein substrate recognition.
  • 35.Hellen CUT, Facke M, Krausslich H-G, Lee C-K, Wimmer E. Characterization of Poliovirus 2A Proteinase by Mutational Analysis: Residues Required for Autocatalytic Activity are Essential for Induction of Cleavage of Eukaryotic Initiation Factor p220. J Virol. 1991;65:4226–4231. doi: 10.1128/jvi.65.8.4226-4231.1991. of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; Polio 2Apro containing a Cysl09Ser substitution within the putative His20, Asp38, Cys109 catalytic triad retains significant autocatalytic activity.
  • 36.Malcolm BA, Chin SM, Jewell DA, Stratton-Thomas JR, Thudium KB, Ralston R, Rosenberg S. Expression and Characterization of Recombinant Hepatitis A Virus 3C Protease. Biochemistry. 1992;31:3358–3363. doi: 10.1021/bi00128a008. of special interest. [DOI] [PubMed] [Google Scholar]; A colorimetric assay was used to characterize cleavage by purified hepatitis A virus 3Cpro.
  • 37.Gorbalenya AE, Koonin EV, Lai MM-C. Identification of Rubi- and Aphthovirus Proteases and Delineation of a Novel Conserved Domain Associated with Proteases of Rubi, α- and Coronaviruses. 6th edn. Vol. 288. 1991. Putative Papain related Thiol Proteases of Positive-strand RNA Viruses; pp. 201–205. (FEBS Lett). of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; Computer-assisted analysis was used to identify the first viral proteinases that are distantly related to papain-like thiol proteinases.
  • 38.Cordingley MG, Callahan PL, Sardana VV, Garsky VM, Colonno RJ. Substrate Requirements of Human Rhinovirus 3C Protease for Peptide Cleavage In Vitro. J Biol Chem. 1990;265:9062–9065. [PubMed] [Google Scholar]
  • 39.Blair WS, Semler BL. Role for the P4 Amino Acid Residue in Substrate Utilization by the Poliovirus 3CD Proteinase. J Virol. 1991;65:6111–6123. doi: 10.1128/jvi.65.11.6111-6123.1991. of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; This paper suggests that the P4 residue is a less important determinant of substrate recognition by 3Cpro than by its precursor 3CDpro.
  • 40.Petithory JR, Masiarz FR, Kirsch JF, Santi DV, Malcolm BA. 6th edn. Vol. 88. 1991. A Rapid Method for Determination of Endoproteinase Substrate Specificity: Specificity of the 3C Proteinase from Hepatitis A Virus; pp. 11510–11514. (Proc Natl Acad Sci USA). of outstanding interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; A novel and rapid technique was used to demonstrate that hepatitis A virus 3Cpro has a strong preference for small residues (Ala, Ser, Gly) at the P1′ position, but has little specificity at P2′.
  • 41.Weidner JR, Dunn BM. Development of Synthetic Peptide Substrates for the Poliovirus 3C Proteinase. Arch Biochem Biophys. 1991;286:402–408. doi: 10.1016/0003-9861(91)90058-q. of special interest. [DOI] [PubMed] [Google Scholar]; A high performance liquid chromatography assay reveals that polio 3Cpro has a strong preference for a proline P2′ residue, and a continuous fluorescence assay is reported.
  • 42.Hellen CUT, Lee C-K, Wimmer E. Determinants of Substrate Recognition by Poliovirus 2A Proteinase. J Virol. 1992;66:3330–3338. doi: 10.1128/jvi.66.6.3330-3338.1992. of special interest. [DOI] [PMC free article] [PubMed] [Google Scholar]; P2 and P1′ positions are strict determinants of substrate recognition by polio 2Apro, but P2′, P1′ and P3 positions are broadly tolerant of substitution. Substrate requirements for cleavage in trans are more stringent than for cleavage in cis.
  • 43.Jewell DA, Swietnicki W, Dunn BM, Malcom BA. Hepatitis A Virus 3C Proteinase Substrate Specificity. Biochemistry. 1992;31:7862–7869. doi: 10.1021/bi00149a017. of special interest. [DOI] [PubMed] [Google Scholar]; Hepatitis A virus 3Cpro has strong preferences for residues at P4 and P1 positions, and differs in specificity from enteroviral 3C proteinases.
  • 44.Singh SB, Cordingley MG, Ball RG, Smith JL, Dombrowski AW, Goetz MA. Structure and Stereochemistry of Thysananone: a Novel Human Rhinovirus 3C Protease Inhibitor from Thyanophora penicilloides. Tetrahedron Lett. 1991;32:5279–5282. of special interest. [Google Scholar]; A novel non-peptide (naphthoquinone) inhibitor of rhinovirus 3C proteinase.
  • 45.Skiles JW, McNeil D. Spiro Indoline Beta-lactams, Inhibitors of Poliovirus and Rhinovirus 3C-proteinases. Tetrahedron Lett. 1990;31:7277–7280. [Google Scholar]

Articles from Current Opinion in Biotechnology are provided here courtesy of Elsevier

RESOURCES